drugset / Trial / NCT02262780

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

NCT02262780

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Group 1: To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T40/H12.5 and T80/H12.5) Group 2: To investigate safety, tolerability and pharmacokinetics of Telmisartan + HCTZ (T80/H12.5 x 7 days)

Timeline

Start
2003-12-01
Primary completion
2004-02-15
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg Oral
Subject Telmisartan Other / unclassified 40 mg Oral
Subject Telmisartan Other / unclassified 80 mg Oral

Indications

No indication recorded.